CY1106359T1 - Νεες μεθοδοι και συνθεσεις πepιεχουσες οπιοειδη και ανταγωνιστες αυτων - Google Patents

Νεες μεθοδοι και συνθεσεις πepιεχουσες οπιοειδη και ανταγωνιστες αυτων

Info

Publication number
CY1106359T1
CY1106359T1 CY20071100318T CY071100318T CY1106359T1 CY 1106359 T1 CY1106359 T1 CY 1106359T1 CY 20071100318 T CY20071100318 T CY 20071100318T CY 071100318 T CY071100318 T CY 071100318T CY 1106359 T1 CY1106359 T1 CY 1106359T1
Authority
CY
Cyprus
Prior art keywords
compositions
opioids
methods
antagonists
preparing
Prior art date
Application number
CY20071100318T
Other languages
English (en)
Inventor
John J. Farrar
Original Assignee
Adolor Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adolor Corporation filed Critical Adolor Corporation
Publication of CY1106359T1 publication Critical patent/CY1106359T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Νέες μέθοδοι και συνθέσεις που περιέχουν οπιοειδή και ανταγωνιστές οπιοειδών. Σε προτιμώμενες ενσωματώσεις, οι μέθοδοι και οι συνθέσεις περιέχουν οπιοειδή και ενώσεις ανταγωνιστών οπιοειδών περιφερειακών mu. Οι μέθοδοι και οι συνθέσεις είναι ιδιαιτέρως κατάλληλες για την θεραπευτική και/ή την προληπτική αγωγή παράπλευρων δράσεων συνδεομένων με οπιοειδή στις οποίες περιλαμβάνονται, παραδείγματος χάρη, δυσκοιλιότητα, έμετος και/ή ναυτία. Τα Σχήματα 2Α και 2Β είναι γραφικές παραστάσεις μελετών επί της αναστολής της ναυτίας και του εμέτου με χρήση μεθόδων συμφώνων προς μια ενσωμάτωση της παρούσας εφεύρεσης.
CY20071100318T 1999-11-29 2007-03-07 Νεες μεθοδοι και συνθεσεις πepιεχουσες οπιοειδη και ανταγωνιστες αυτων CY1106359T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45080699A 1999-11-29 1999-11-29
PCT/US2000/042315 WO2001037785A2 (en) 1999-11-29 2000-11-29 Novel methods and compositions involving opioids and antagonists thereof

Publications (1)

Publication Number Publication Date
CY1106359T1 true CY1106359T1 (el) 2011-10-12

Family

ID=23789563

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100318T CY1106359T1 (el) 1999-11-29 2007-03-07 Νεες μεθοδοι και συνθεσεις πepιεχουσες οπιοειδη και ανταγωνιστες αυτων

Country Status (13)

Country Link
EP (1) EP1244447B1 (el)
JP (1) JP2003528819A (el)
AU (1) AU784541B2 (el)
CA (1) CA2392362A1 (el)
CY (1) CY1106359T1 (el)
DE (1) DE60032940T2 (el)
DK (1) DK1244447T3 (el)
ES (1) ES2278647T3 (el)
IL (2) IL149600A0 (el)
MX (1) MXPA02005335A (el)
NZ (1) NZ518562A (el)
PT (1) PT1244447E (el)
WO (1) WO2001037785A2 (el)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
RS50070B (sr) 1997-12-22 2009-01-22 Euro-Celtique S.A., Oralni dozni oblik sa kombinacijom opijatnog agonista i antagonista
EP2517710B1 (en) 2000-02-08 2015-03-25 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
AU2002314967B2 (en) * 2001-06-05 2007-09-20 University Of Chicago Use of methylnaltrexone to treat immune suppression
ATE419039T1 (de) 2001-07-18 2009-01-15 Euro Celtique Sa Pharmazeutische kombinationen von oxycodon und naloxon
DE60232417D1 (de) 2001-08-06 2009-07-02 Euro Celtique Sa Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
DK2425824T5 (en) 2002-04-05 2018-02-12 Mundipharma As Pharmaceutical preparation containing oxycodone and naloxone
EP2422772A3 (en) 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
DK2368553T3 (en) 2003-04-08 2015-02-09 Progenics Pharm Inc Pharmaceutical preparation comprising methylnaltrexone
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US6992090B2 (en) * 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
US7700626B2 (en) * 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
WO2006064780A1 (ja) * 2004-12-14 2006-06-22 Shionogi & Co., Ltd. 便秘治療剤
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US20060211733A1 (en) * 2005-03-04 2006-09-21 Adolor Corporation Methods of preventing and treating opioid bowel dysfunction
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CN101171010B (zh) 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
WO2006126529A1 (ja) * 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
EP1762569A1 (en) * 2005-09-12 2007-03-14 Alcasynn Pharmaceuticals Gmbh Novel 6-amino-morphinan derivatives, method of manufacturing them and their application as analgesics
JP5176188B2 (ja) 2006-04-21 2013-04-03 ディーエスエム アイピー アセッツ ビー．ブイ． オピオイド受容体拮抗薬の使用
KR101486228B1 (ko) 2006-06-19 2015-01-26 알파마 파머슈티컬스 엘엘씨 약제학적 조성물
PT2139890E (pt) 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
PL2137191T3 (pl) 2007-03-29 2016-12-30 Antagoniści obwodowego receptora opioidowego i ich zastosowania
EP2134718A2 (en) 2007-03-29 2009-12-23 Progenics Pharmaceuticals, Inc. Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof
CN101827819B (zh) 2007-08-09 2013-06-12 伦斯勒理工学院 阿片样物质酰胺季铵盐
JP5905198B2 (ja) * 2007-10-01 2016-04-20 ザ ユニヴァーシティー オヴ シカゴ 薬剤誘発性吐き気のオピオイド拮抗薬による治療
CA2707174C (en) * 2007-11-30 2013-12-31 Purdue Pharma L.P. Benzomorphan compounds
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
WO2010103039A1 (en) 2009-03-10 2010-09-16 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
HUE043963T2 (hu) 2009-12-04 2019-09-30 Alkermes Pharma Ireland Ltd Morfinán származékok gyógyszer-túladagolás kezelésére
AU2011232628B2 (en) 2010-03-22 2015-04-09 Rensselaer Polytechnic Institute Morphinane derivatives containing a carboxamide group as opioid receptor ligands
AU2011293502B2 (en) 2010-08-23 2015-03-19 Alkermes Pharma Ireland Limited Methods for treating antipsychotic-induced weight gain
SI2725908T1 (sl) 2011-06-29 2017-10-30 Alkermes, Inc. Periferno delujoče opioidne spojine
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US10072018B2 (en) 2013-04-17 2018-09-11 Biopharma Works Compounds for treatment of pain
WO2014172482A1 (en) * 2013-04-17 2014-10-23 Robert Alfred Volkmann Compounds for treatment of pain
AU2014295042B2 (en) 2013-07-23 2017-03-30 Mundipharma Pty Limited A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
KR102201609B1 (ko) * 2019-04-19 2021-01-12 연성정밀화학(주) 날데메딘의 제조방법
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4769372A (en) * 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
ES2058265T3 (es) * 1987-04-16 1994-11-01 Lilly Co Eli Piperidinas antagonistas de opiaceos.
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists

Also Published As

Publication number Publication date
EP1244447A4 (en) 2003-06-04
AU3970601A (en) 2001-06-04
PT1244447E (pt) 2007-02-28
WO2001037785A2 (en) 2001-05-31
WO2001037785A3 (en) 2002-01-10
WO2001037785A9 (en) 2002-08-29
EP1244447B1 (en) 2007-01-10
EP1244447A2 (en) 2002-10-02
AU784541B2 (en) 2006-04-27
IL149600A0 (en) 2002-11-10
IL149600A (en) 2010-06-16
NZ518562A (en) 2005-04-29
DE60032940D1 (de) 2007-02-22
DK1244447T3 (da) 2007-04-23
ES2278647T3 (es) 2007-08-16
JP2003528819A (ja) 2003-09-30
CA2392362A1 (en) 2001-05-31
MXPA02005335A (es) 2003-01-28
DE60032940T2 (de) 2007-11-08

Similar Documents

Publication Publication Date Title
CY1106359T1 (el) Νεες μεθοδοι και συνθεσεις πepιεχουσες οπιοειδη και ανταγωνιστες αυτων
ES2159839T3 (es) Derivados del propano, su preparacion y su uso.
CY1106600T1 (el) Ανθεκτικη, στη φθορα συνεξωθημενη μορφη δοσολογιας που περιεχει εναν ενεργο παραγοντα και εναν ανταγωνιστικο παραγοντα και διαδικασια παρασκευης αυτης
EA200101177A1 (ru) Производные индола в качестве антагонистов прогестерона
ATE349440T1 (de) Als antikrebsmittel verwendbare heterocyklische derivate
CY1106257T1 (el) ΧΡΗΣΗ ΠΑΡΑΓΩΓΩΝ ΠΥΡΙΔΑΖΙΝΟ [4,5-(b)]-ΙΝΔΟΛΗ -1-ΑΚΕΤΑΜΙΔΗ ΓΙΑ ΤΗΝ ΠΑΡΑΣΚΕΥΗ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΣΚΕΥΑΣΜΑΤΩΝ ΠΟΥ ΠΡΟΟΡΙΖΟΝΤΑΙ ΓΙΑ ΝΟΣΟΥΣ ΠΟΥ ΣΥΝΔΕΟΝΤΑΙ ΜΕ ΤΗ ΔΥΣΛΕΙΤΟΥΡΓΙΑ ΤΩΝ ΥΠΟΔΟΧΕΩΝ ΠEPΙΦEPΙΚΟΥ ΤΥΠΟΥ ΣΤΙΣ ΒΕΝΖΟΔΙΑΖΕΠΙΝΕΣ
CH1175401H9 (de) Piperazin Derivate verwendbar als CCR5 Antagonist en
TR199801555T2 (xx) Topoizomeraz inhibit�rleri olarak koralin analoglar�.
TR200102029T2 (tr) 1-Heterosiklil ikameli diarilaminler.
CY1108339T1 (el) Παραγωγα spiro(2h-1-benzopyran-2,4´-piperidine) ως αναστολεις της μεταφορας γλυκινης
TR199802269T2 (xx) Endotelin resept�r antagonistleri olarak faydal� indol t�revleri.
DE60021282D1 (de) Carbamat-derivate als muscarin-rezeptor antonisten
HUT74992A (en) Use of serotonin antagonist indol derivatives for producing pharmaceutical compositions using for treating fibromyalgia
DE60135485D1 (de) Monozyklische oder bizyklische carbozyklen und heterozyklen als hemmer von factor xa
ES2072096T3 (es) 4-fenilpiperidinas n-sustituidas antagonistas de opioides.
TR200000520A2 (tr) 4-Fenil-piridin türevleri.
HUP0301573A2 (hu) Szubsztituált arilpirazinok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
BR9206237A (pt) Uso de derivados de tetrahidrocarbazole como receptores agonistas 5-HT1.
SE9702773D0 (sv) Novel compounds
EA200300593A1 (ru) Соединения пиперазинилпиразинов в качестве агонистов или антагонистов серотонин 5-ht2 рецептора
TNSN05133A1 (en) Imidazoquinoline derivatives as adenosine a3 receptor ligands
ME00056B (me) Kombinacija kombrestatina i anti-kancer agensa
TR200200359T2 (tr) Cgrp Antagonist'lerinin ve cgrp-release (Gevşeme)-Engelleyici Menopoza Bağlı Deri Kızarıklıklarında Kullanılması
TR199902848T2 (xx) Ergolin t�revleri ve bunlar�n somatostatin resept�r antagonist olarak kullan�mlar�
TR200403436T2 (tr) Kristalin 1-metilkarbapenem türevleri.